Given the central contribution of Pgam5 to numerous inflammation-related diseases, the design of novel drugs targeting Pgam5 seems to be a critical method for the management of endotoxemia-induced organ dysfunction. The gene discussed is PGAM5; the disease is serum lipopolysaccharide activity.